--- title: "Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277964912.md" description: "Compass Therapeutics (NASDAQ:CMPX) reported earnings of ($0.09) EPS for the quarter, surpassing estimates of ($0.10) by $0.01. Following the announcement, the stock rose 2.5% to $5.83. The company has a market cap of $1.04 billion and a PE ratio of -12.96. Institutional investors hold 68.43% of the stock. Analysts have mixed ratings, with a consensus of \"Moderate Buy\" and a target price of $13.36. Compass focuses on developing immuno-oncology therapies, including bispecific antibodies targeting PD-1 and PD-L1 checkpoints." datetime: "2026-03-05T16:15:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277964912.md) - [en](https://longbridge.com/en/news/277964912.md) - [zh-HK](https://longbridge.com/zh-HK/news/277964912.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277964912.md) | [English](https://longbridge.com/en/news/277964912.md) # Compass Therapeutics (NASDAQ:CMPX) Releases Earnings Results, Beats Estimates By $0.01 EPS Compass Therapeutics (NASDAQ:CMPX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01, FiscalAI reports. Get **Compass Therapeutics** alerts: ## Compass Therapeutics Stock Up 2.5% - Top 3 High-Momentum Companies Analysts Are Still Bullish On CMPX traded up $0.14 during trading on Thursday, hitting $5.83. The company had a trading volume of 453,195 shares, compared to its average volume of 2,287,071. The company has a market capitalization of $1.04 billion, a PE ratio of -12.96 and a beta of 1.48. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The firm's 50-day moving average price is $5.88 and its 200 day moving average price is $4.77. ## Institutional Trading of Compass Therapeutics A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Xponance LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $55,000. CIBC Bancorp USA Inc. acquired a new position in Compass Therapeutics during the third quarter worth $37,000. Creative Planning bought a new position in Compass Therapeutics in the second quarter valued at $30,000. Finally, Victory Capital Management Inc. increased its stake in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after buying an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors. ## Wall Street Analyst Weigh In A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an "outperform" rating for the company. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research note on Wednesday, February 4th. Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They set a "buy" rating and a $15.00 target price for the company. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $13.36. **Get Our Latest Stock Report on Compass Therapeutics** ## Compass Therapeutics Company Profile (Get Free Report) Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment. The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells. ## Featured Stories - Five stocks we like better than Compass Therapeutics - The gold chart Wall Street is terrified of… - America’s 1776 happening again - Buy this Gold Stock Before May 2026 - What a Former CIA Agent Knows About the Coming Collapse - “Fed Proof” Your Bank Account with THESE 4 Simple Steps _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Compass Therapeutics Right Now? Before you consider Compass Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list. While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相關股票 - [Compass Therapeutics (CMPX.US)](https://longbridge.com/zh-HK/quote/CMPX.US.md) ## 相關資訊與研究 - [AstraZeneca's Combo Therapy Shows Improved Progression-free Survival in Late-stage Liver Cancer Trial](https://longbridge.com/zh-HK/news/281477081.md) - [Vinci Compass Investments (NASDAQ:VINP) CFO Sergio Passos Ribeiro Sells 1,325 Shares](https://longbridge.com/zh-HK/news/281664366.md) - [ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH](https://longbridge.com/zh-HK/news/281541014.md) - [PreveCeutical Adopts Semi-Annual Financial Reporting | PRVCF Stock News](https://longbridge.com/zh-HK/news/281417668.md) - [Iterative Health and US Heart & Vascular Enter Strategic Partnership to Advance Community-Based Cardiovascular Research](https://longbridge.com/zh-HK/news/281515921.md)